University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Peter R. Carroll, MD, MPH

Peter R. Carroll, MD, MPH

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF
Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Cancer Center Program Memberships

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Education

University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008
 


Professional Experience

  • 1984-1986
    Fellow, Urology Service, Memorial Sloan-Kettering Cancer Center
  • 1986-1992
    Assistant Professor in Residence, Dept. of Urology, University of California, S.F
  • 1992-1993
    Associate Professor, Dept. of Urology, University of California, San Francisco
  • 1996-present
    Program Leader, Program in Urologic Oncology, UCSF Cancer Center
  • 1996-present
    Professor and Chair, Department of Urology, UCSF, San Francisco, CA
  • 2003-present
    Surgeon-in-Chief, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Director of Clinical Services and Strategic Planning, UCSF Helen Diller Family Comprehensive Cancer Center
  • 2006-present
    Associate Dean, UCSF School of Medicine

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Washington SL, Baskin AS, Ameli N, Nguyen HG, Westphalen AC, Shinohara K, Carroll PR. MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. AJR Am J Roentgenol. 2020 Jan 08; 1-5.
    View on PubMed
  2. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Med. 2019 Nov 12.
    View on PubMed
  3. Ten Ham RMT, Broering JM, Cooperberg M, Carroll P, Wilson LS. Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clin Genitourin Cancer. 2019 Nov 06.
    View on PubMed
  4. Overland MR, Washington SL, Carroll PR, Cooperberg MR, Herlemann A. Active surveillance for intermediate-risk prostate cancer: yes, but for whom? Curr Opin Urol. 2019 Nov; 29(6):605-611.
    View on PubMed
  5. Schenk JM, Newcomb LF, Zheng Y, Faino AV, Zhu K, Nyame YA, Brooks JD, Carroll PR, Cooperberg MR, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Lin DW. African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study (PASS). J Urol. 2019 Oct 25; 101097JU0000000000000621.
    View on PubMed
  6. Bjurlin MA, Carroll PR, Eggener S, Fulgham PF, Margolis DJ, Pinto PA, Rosenkrantz AB, Rubenstein JN, Rukstalis DB, Taneja SS, Turkbey B. Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. J Urol. 2019 Oct 23; 101097JU0000000000000617.
    View on PubMed
  7. Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. 2019 Oct 22.
    View on PubMed
  8. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. Reply by Authors. J Urol. 2019 11; 202(5):958.
    View on PubMed
  9. Gross MD, Sedrakyan A, Bianco FJ, Carroll PR, Daskivich TJ, Eggener SE, Ehdaie B, Fisher B, Gorin MA, Hunt B, Jiang H, Klein EA, Marinac-Dabic D, Montgomery JS, Polascik TJ, Priester AM, Rastinehad AR, Viviano CJ, Wysock JS, Hu JC. SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer. J Urol. 2019 11; 202(5):952-958.
    View on PubMed
  10. Carroll PR, Witte JS, Parsons JK. Germline testing in those at risk of prostate cancer. Can J Urol. 2019 Oct; 26(5S2):31-33.
    View on PubMed
  11. Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Hu JC, Hussain M, King M, Klein E, Kungel T, Makarov D, Pinto PA, Rini B, Roach M, Sandler H, Schlegel PN, Song D, Goldberg K, Pazdur R, Beaver JA. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop. J Urol. 2019 Sep 10; 101097JU0000000000000532.
    View on PubMed
  12. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019 10; 202(4):702-709.
    View on PubMed
  13. Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Edwards M, Sangar S, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, Graf R, Rodriquez A, Suraneni M, Wang Y, Landers M, Carroll P, Cooperberg MR, Dittamore R, Paris PL. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer. J Urol. 2019 10; 202(4):732-741.
    View on PubMed
  14. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2019 10; 202(4):696-701.
    View on PubMed
  15. Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM. Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. J Urol. 2019 10; 202(4):689-695.
    View on PubMed
  16. Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM. Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiol Biomarkers Prev. 2019 Nov; 28(11):1917-1925.
    View on PubMed
  17. Herlemann A, Huang HC, Alam R, Tosoian JJ, Kim HL, Klein EA, Simko JP, Chan JM, Lane BR, Davis JW, Davicioni E, Feng FY, McCue P, Kim H, Den RB, Bismar TA, Carroll PR, Cooperberg MR. Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance. Prostate Cancer Prostatic Dis. 2019 Aug 27.
    View on PubMed
  18. Drost FH, Nieboer D, Morgan TM, Carroll PR, Roobol MJ. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts. Eur Urol. 2019 Nov; 76(5):693-702.
    View on PubMed
  19. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. J Urol. 2019 09; 202(3):506-510.
    View on PubMed
  20. Carroll PR, Parsons JK. Guidelines should be assessed based on the underlying evidence. CMAJ. 2019 Aug 06; 191(31):E871.
    View on PubMed

Go to UCSF Profiles, powered by CTSI